Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care survey

Abstract excerpt

Abstract Background The use of CDKN2A/B deletions in the current WHO CNS classification (5th edition, 2021), has led to some ambiguity in patient management. Further clinical studies are required to fully ascertain the clinical impact of CDKN2A/B deletions in this patient cohort and their optimal management. To this end, we conducted a multi-center retrospective cohort study and patterns of care survey to explore...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Metastases and Treatment
• Share to Glioma Diagnosis and Treatment
• Share to Neuroblastoma Research and Treatments